Brentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial.
暂无分享，去创建一个
E. Cesarman | P. Moore | L. Ratner | N. Mounier | M. Rudek | Camille E. Demarco | R. Ambinder | A. Chadburn | M. Bimali | D. Henry | A. Noy | Y. Taoufik | E. Sharon | C. Besson | R. Mitsuyasu | E. Reid | J. Ramos | P. Rubinstein | Jeanette Y. Lee | Dominique Costagliola